HLS Therapeutics Inc Stock Toronto S.E.
Stocks
AM
CA05328X1015
Pharmaceuticals
OTC Markets Traded| Market Cap | 88.49M 75.8M 70.92M 64.92M 122M 8.47B 123M 838M 327M 4.25B 332M 325M 14.07B | P/E 2026 * |
-13.8x | P/E 2027 * | -40.9x |
|---|---|---|---|---|---|
| Enterprise Value | 88.49M 75.8M 70.92M 64.92M 122M 8.47B 123M 838M 327M 4.25B 332M 325M 14.07B | EV / Sales 2026 * |
1.51x | EV / Sales 2027 * | 1.36x |
| Free-Float |
99.46% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HLS Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 58 | 2023-04-30 |
John Hanna
DFI | Director of Finance/CFO | 61 | 2024-01-25 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 61 | 2014-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Rodney Hill
BRD | Director/Board Member | 58 | 2018-03-11 |
John Welborn
CHM | Chairman | 48 | 2023-06-21 |
Norma Beauchamp
BRD | Director/Board Member | 65 | 2020-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.41% | - | - | 88.49M | |
| +2.40% | -1.16% | +21.66% | +101.69% | 97.79B | |
| +0.46% | -2.41% | +51.42% | +163.99% | 53.13B | |
| 0.00% | -2.68% | +2.47% | +279.08% | 23.75B | |
| -2.82% | -3.52% | -14.88% | -15.90% | 8.28B | |
| -6.08% | -4.94% | -38.65% | -25.33% | 7.8B | |
| +0.42% | -0.54% | -15.53% | -21.46% | 6.6B | |
| +0.88% | -2.29% | +5.50% | +17.12% | 6.29B | |
| -0.91% | +1.36% | -3.76% | +18.34% | 5.16B | |
| +1.07% | +3.59% | +8.68% | +20.01% | 3.72B | |
| Average | -0.43% | -1.28% | +1.88% | +59.73% | 23.61B | |
| Weighted average by Cap. | +1.14% | -1.82% | +20.84% | +118.07% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 58.44M 50.06M 46.84M 42.87M 80.46M 5.59B 81.53M 553M 216M 2.81B 219M 215M 9.29B | 65.03M 55.7M 52.12M 47.71M 89.53M 6.22B 90.72M 616M 240M 3.13B 244M 239M 10.34B |
| Net income | -5.47M -4.69M -4.38M -4.01M -7.53M -523M -7.63M -51.79M -20.2M -263M -20.54M -20.09M -870M | -2.16M -1.85M -1.73M -1.59M -2.98M -207M -3.02M -20.5M -7.99M -104M -8.13M -7.95M -344M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
